drugset / Trial / NCT05924893

The Use of Naltrexone Hydrochloride to Promote Healing in Patients With Resistant Non-infectious Corneal Ulcer

NCT05924893

Completed 50 enrolled Minia University
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The opioid growth factor-receptor antagonist-naltrexone hydrochloride (NTX)- has gained much reach interest for applications in ophthalmology, because of its novel mechanism of action for speeding up corneal wound healing in both diabetics and non-diabetics, effective both locally and systemically and its availability as a low molecular weight synthetic drug.

Timeline

Start
2021-01-01
Primary completion
2022-06-01
Completion
2022-12-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboxymethylcellulose Other / unclassified
Subject Naltrexone Small molecule Other

Indications